Literature DB >> 21319958

Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites.

S K Bae1, Y-J Jeong, C Lee, K-H Liu.   

Abstract

Uridine 5'-diphosphate-glucuronosyltransferases (UGTs) involved in the glucuronide formation of efavirenz (EFV) and its three hydroxy metabolites, 8-hydroxyefavirenz (8-OH EFV), 7-hydroxyefavirenz (7-OH EFV), and 8,14-dihydroxyefavirenz (8,14-diOH EFV), were assessed. Among 12 recombinant UGT isoforms tested, only UGT2B7 showed catalytic activity in the formation of EFV-N-glucuronide (EFV-G) as previously reported. On the other hand, almost all UGT isoforms were involved in the glucuronidation of the three hydroxy metabolites, although their relative contribution is unclear. The catalytic activities in the formation of EFV-G by 17 different human liver microsomes exhibit a more than 40-fold inter-individual variability, whereas those of glucuronidation of the three hydroxy metabolites showed almost identical activity. The formation of EFV-G showed a significant correlation (r = 0.920; p < 0.0001) with UGT2B7-catalysed azidothymidine glucuronidation in 17 different human liver microsomes. Furthermore, fluconazole, a known UGT2B7 inhibitor, potently inhibited the formation of EFV-G up to 80%. This suggests that EFV might be a specific UGT2B7 substrate in vitro. This is the first study identifying specific UGT isozymes that glucuronidate EFV and its three hydroxy metabolites. Continued identification and characterisation of these pathways may help reduce adverse effects such as CNS toxicity in EFV therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21319958     DOI: 10.3109/00498254.2011.551849

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  11 in total

1.  Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.

Authors:  V Michaud; E Ogburn; N Thong; A O Aregbe; T C Quigg; D A Flockhart; Z Desta
Journal:  Clin Pharmacol Ther       Date:  2012-02-08       Impact factor: 6.875

2.  Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals.

Authors:  Tailah Bernardo de Almeida; Marcelo Costa Velho Mendes de Azevedo; Jorge Francisco da Cunha Pinto; Fernando Rafael de Almeida Ferry; Guilherme Almeida Rosa da Silva; Izana Junqueira de Castro; Paxton Baker; Amilcar Tanuri; David W Haas; Cynthia C Cardoso
Journal:  J Antimicrob Chemother       Date:  2018-09-01       Impact factor: 5.790

Review 3.  PharmGKB summary: Efavirenz pathway, pharmacokinetics.

Authors:  Ellen M McDonagh; Johnathan L Lau; Maria L Alvarellos; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-07       Impact factor: 2.089

4.  Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index.

Authors:  Fen Jiang; Zeruesenay Desta; Ji-Hong Shon; Chang-Woo Yeo; Ho-Sook Kim; Kwang-Hyeon Liu; Soo-Kyung Bae; Sang-Seop Lee; David A Flockhart; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

5.  Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.

Authors:  Getnet Yimer; Nobuhisa Ueda; Abiy Habtewold; Wondwossen Amogne; Akira Suda; Klaus-Dieter Riedel; Jürgen Burhenne; Getachew Aderaye; Lars Lindquist; Eyasu Makonnen; Eleni Aklillu
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

6.  Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.

Authors:  V Michaud; Y Kreutz; T Skaar; E Ogburn; N Thong; D A Flockhart; Z Desta
Journal:  Pharmacogenomics J       Date:  2013-04-30       Impact factor: 3.550

7.  Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes.

Authors:  Hye Young Ji; Hyeri Lee; Sae Rom Lim; Jeong Han Kim; Hye Suk Lee
Journal:  Molecules       Date:  2012-01-17       Impact factor: 4.411

Review 8.  Pharmacogenomics of Antiretroviral Drug Metabolism and Transport.

Authors:  Zaikuan J Yu; Eric P Mosher; Namandjé N Bumpus
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-09-22       Impact factor: 13.820

9.  An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients.

Authors:  Marelize Swart; Jonathan Evans; Michelle Skelton; Sandra Castel; Lubbe Wiesner; Peter J Smith; Collet Dandara
Journal:  Front Genet       Date:  2016-01-07       Impact factor: 4.599

10.  Influence of SULT1A1*2 Polymorphism on Plasma Efavirenz Concentration in Thai HIV-1 Patients.

Authors:  Monpat Chamnanphon; Rattanaporn Sukprasong; Andrea Gaedigk; Weerawat Manosuthi; Pajaree Chariyavilaskul; Supeecha Wittayalertpanya; Napatrupron Koomdee; Thawinee Jantararoungtong; Apichaya Puangpetch; Chonlaphat Sukasem
Journal:  Pharmgenomics Pers Med       Date:  2021-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.